The Comprehensive Genetic Test for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) utilizes next-generation sequencing (NGS) to examine 10 genes associated with catecholaminergic ventricular tachycardia and calcium handling disorders. It is a targeted gene panel specifically designed to support accurate diagnosis, risk assessment, and prevention.
More Information
The Comprehensive Genetic Test for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a targeted genetic test designed to evaluate hereditary causes of catecholaminergic polymorphic ventricular tachycardia (CPVT), a cardiac arrhythmia disorder triggered by adrenergic stimulation. The comprehensive genetic test for catecholaminergic polymorphic ventricular tachycardia (CPVT) includes the analysis of 10 genes, along with selected non-coding variants, enabling a comprehensive assessment of genetic factors associated with this condition. It is particularly suitable for individuals with a clinical suspicion of catecholaminergic polymorphic ventricular tachycardia. This disorder is characterized by abnormal cardiac rhythm occurring in response to physical activity or emotional stress, in the absence of structural heart disease.
The comprehensive genetic test for catecholaminergic polymorphic ventricular tachycardia (CPVT) includes key genes such as RYR2, CASQ2, CALM1, CALM2, and TRDN, which are involved in calcium handling and regulation within cardiac cells. RYR2 encodes a calcium release channel in the sarcoplasmic reticulum, while CASQ2 plays a role in calcium storage. CALM genes are involved in calcium signaling, and TRDN contributes to the stabilization of calcium release complexes. These pathways are essential for proper excitation-contraction coupling in the heart. Disruptions in these mechanisms lead to abnormal calcium release and increased susceptibility to stress-induced arrhythmias. The comprehensive genetic test for catecholaminergic polymorphic ventricular tachycardia (CPVT) is indicated in individuals presenting with symptoms or clinical findings suggestive of catecholaminergic polymorphic ventricular tachycardia (CPVT).
The clinical spectrum of CPVT includes exercise- or stress-induced ventricular arrhythmias, which may present with dizziness, light-headedness, syncope, or sudden cardiac arrest. Symptoms typically begin in childhood, although presentation may vary. In the absence of diagnosis and management, episodes may progress to life-threatening ventricular tachycardia or fibrillation. Individuals are usually structurally normal on cardiac imaging, making clinical recognition more challenging. The severity and frequency of arrhythmic events vary among affected individuals, contributing to clinical heterogeneity.
The purpose of the comprehensive genetic test for catecholaminergic polymorphic ventricular tachycardia (CPVT) is to identify pathogenic variants associated with catecholaminergic polymorphic ventricular tachycardia (CPVT), supporting accurate diagnosis and differentiation from other arrhythmia disorders with similar clinical features. Genetic findings contribute to improved understanding of the molecular mechanisms underlying calcium dysregulation in cardiac cells and support appropriate disease classification. The identification of specific genetic alterations assists in risk assessment, prognosis evaluation, and the development of individualized long-term monitoring strategies.
A higher genetic risk is confirmed when pathogenic mutations are found in genes associated with catecholaminergic polymorphic ventricular tachycardia (CPVT), including RYR2, CASQ2, and CALM1. A lower risk may be inferred when no mutations are detected, though comprehensive clinical follow-up is still essential. The integration of genetic data with clinical findings and electrophysiological evaluation is critical for precise diagnosis, prognosis, and long-term patient care.
The test is performed in a clinical laboratory accredited to ISO 15189 and certified by CLIA and CAP, ensuring the validity, accuracy and international recognition of the results.
